Elazar Rabbani et al.

Serial No.: 08/978,633

Filed: November 25, 1997

Page 2 Amendment and Reply To May 11, 2011 Office Action

## **CLAIM LISTING**

Claims 1-244 (Canceled)

245. (Previously Presented) A nucleic acid construct comprising at least three nucleic acid strands:

- (a) a first nucleic acid strand, wherein said first nucleic acid strand is a circular strand;
- (b) a second nucleic acid strand, wherein said second nucleic acid strand is fully complementary to said first nucleic acid strand;
- (c) a third nucleic acid strand comprising a first portion complementary to said first nucleic acid strand and a second portion not complementary to said first nucleic acid strand and said second nucleic acid strand,

wherein when said first nucleic acid strand is hybridized to said second nucleic acid strand to form a double stranded portion, said double-stranded portion forms a template for synthesis of a nucleic acid product when present in a cell;

wherein when said first nucleic acid strand is hybridized to said first portion of said third nucleic acid strand, said second nucleic acid strand and said first portion of said third nucleic acid strand form a gapped circle, and said second portion of said third nucleic acid strand forms a linear tail, wherein

said linear tail is covalently attached to an antibody or is hybridized to a fourth nucleic acid strand that is covalently attached to an antibody.

246. (Original) The construct of claim 245 wherein said antibody comprises a polyclonal or monoclonal antibody.

247-307 (Canceled)